Press Room

    Back

    Press Release - May 06, 2008

    Sernova Concludes Successful Pre-IND Meeting with FDA


    London, Ontario - May 6, 2008 - Sernova Corp. (TSX-V: SVA)

    Sernova Corp. today announced the successful conclusion of a meeting with the U.S. Food and Drug Administration (FDA) that established definitive requirements for the filing of an Investigational New Drug (IND) application, which is required to advance Sertolin into human Clinical Trials. Sertolin is the Corporation's proprietary technology for treating insulin-dependent diabetes. After review of Sernova's pre-clinical testing data in rodents to date, the FDA specified that the next stage will be a pivotal pre- clinical trial consisting of a single large animal trial with clear endpoints, leading to a Phase I/II human Clinical Trial. The pivotal pre-clinical trial is expected to take about 18 months to complete and will assess the long- term safety and durable activity of Sertolin.

    Justin Leushner, President of Sernova, noted "This key development reflects the interest of the FDA in diabetes therapies, and creates a definitive path for Sernova to initiate "first in man" Clinical Trials to advance our unique technology through the regulatory process required for human use."

    The FDA meetings clarified the details of the development path for Sernova's xenotransplantation approach to treat diabetes, which incorporates co-transplantation of insulin- producing porcine islet cells and Sertoli cells within a small subcutaneous medical device. "Sernova appreciates the positive instruction and interactions we received in our pre-IND meeting with the FDA," said Dr. David White, Lead Scientist for Sernova. "Their clear advice and direction will greatly assist our future IND application as we look toward the crucial Clinical Trials in humans."

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: TEL: (888) 318-7062 info@sernova.com www.sernova.com

    THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →